Skip to main content

Advertisement

Log in

Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The optimal treatment strategy for ductal carcinoma in situ (DCIS) continues to evolve and should consider the consequences of initial treatment on the likelihood, type, and treatment of recurrences.

Methods

We conducted a retrospective cohort study using two data sources of patients who experienced a recurrence (DCIS or invasive cancer) following breast-conserving surgery (BCS) for index DCIS: patients with an index DCIS diagnosed from 1997 to 2008 at the academic institutions of the National Comprehensive Cancer Network (NCCN; N = 88) and patients with an index DCIS diagnosed from 1990 to 2001 at community-based integrated healthcare delivery sites of the Health Maintenance Organization Cancer Research Network (CRN) (N = 182).

Results

Just under half of local recurrences in both cohorts were invasive cancer. While 40 % of patients in both cohorts underwent mastectomy alone at recurrence, treatment of the remaining patients varied. In the earlier CRN cohort, most other patients underwent repeat BCS (39 %) with only 18 % receiving mastectomy with reconstruction, whereas only 16 % had repeat BCS and 44 % had mastectomy with reconstruction in the NCCN cohort. Compared with patients not treated with radiation, those who received radiation for index DCIS were less likely to undergo repeat BCS (NCCN: 6.6 vs. 37 %, p = 0.001; CRN: 20 vs. 48 %, p = 0.0004) and more likely to experience surgical complications after treatment of recurrence (NCCN: 15 vs. 4 %, p = 0.17; CRN: 40 vs. 25 %, p = 0.09).

Conclusion

We found that treatment of recurrences after BCS and subsequent complications may be affected by the use of radiotherapy for the index DCIS. Initial treatment of DCIS may have long-term implications that should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sumner WE 3rd, Koniaris LG, Snell SE, et al. Results of 23,810 cases of ductal carcinoma-in situ. Ann Surg Oncol. 2007;14:1638–43.

    Article  PubMed  Google Scholar 

  2. Morrow M, Schmidt R, Cregger B, Hassett C, Cox S. Preoperative evaluation of abnormal mammographic findings to avoid unnecessary breast biopsies. Arch Surg. 1994;129:1091–6.

    Article  PubMed  CAS  Google Scholar 

  3. Alexander HR, Candela FC, Dershaw DD, Kinne DW. Needle-localized mammographic lesions: results and evolving treatment strategy. Arch Surg. 1990;125:1441–4.

    Article  PubMed  CAS  Google Scholar 

  4. Silverstein MJ, Gamagami P, Colburn WJ, et al. Nonpalpable breast lesions: diagnosis with slightly overpenetrated screen-film mammography and hook wire-directed biopsy in 1,014 cases. Radiology. 1989;171:633–8.

    Article  PubMed  CAS  Google Scholar 

  5. Wilhelm MC, Edge SB, Cole DD, de Paredes E, Frierson HF Jr. Nonpalpable invasive breast cancer. Ann Surg. 1991;213:600–3. discussion 3–5.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. American Cancer Society. Cancer facts & figures 2008. Atlanta: American Cancer Society;2008.

    Google Scholar 

  7. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853: a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.

    Article  PubMed  Google Scholar 

  8. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–18.

    Article  PubMed  CAS  Google Scholar 

  9. Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45:536–43.

    Article  PubMed  Google Scholar 

  10. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102.

    Article  PubMed  Google Scholar 

  11. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–8.

    Article  PubMed  Google Scholar 

  12. Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 2007;101:335–47.

    Article  PubMed  Google Scholar 

  13. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105:701–10.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Vicini FA, Beitsch PD, Quiet CA, et al. First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer. 2005;104:1138–48.

    Article  PubMed  Google Scholar 

  15. Benitez PR, Streeter O, Vicini F, et al. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg. 2006;192:427–33.

    Article  PubMed  Google Scholar 

  16. Beitsch PD, Wilkinson JB, Vicini FA, et al. Tumor bed control with balloon-based accelerated partial breast irradiation: incidence of true recurrences versus elsewhere failures in the American Society of Breast Surgery MammoSite® Registry Trial. Ann Surg Oncol. 2012;19:3165–70.

    Article  PubMed  Google Scholar 

  17. Shah C, McGee M, Wilkinson JB, et al. Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. Clin Breast Cancer. 2012;12:259–63.

    Article  PubMed  Google Scholar 

  18. Park SS, Grills IS, Chen PY, et al. Accelerated partial breast irradiation for pure ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2011;81:403–8.

    Article  PubMed  Google Scholar 

  19. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001.

    Article  PubMed  Google Scholar 

  20. Parrett BM, Schook C, Morris D. Breast reduction in the irradiated breast: evidence for the role of breast reduction at the time of lumpectomy. Breast J. 2010;16:498–502.

    Article  PubMed  Google Scholar 

  21. Khansa I, Colakoglu S, Curtis MS, et al. Postmastectomy breast reconstruction after previous lumpectomy and radiation therapy: analysis of complications and satisfaction. Ann Plast Surg. 2011;66:444–51.

    Article  PubMed  CAS  Google Scholar 

  22. Cordeiro PG, Snell L, Heerdt A, McCarthy C. Immediate tissue expander/implast breast reconstruction after salvage mastectomy for cancer recurrence following lumpectomy/irradiation. Plast Reconstr Surg. 2012;129:341–50.

    Article  PubMed  CAS  Google Scholar 

  23. Chadha M, Feldman S, Boolbol S, Wang L, Harrison LB. The feasibility of a second lumpectomy and breast brachytherapy for localized cancer in a breast previously treated with lumpectomy and radiation therapy for breast cancer. Brachytherapy. 2008;7:22–8.

    Article  PubMed  Google Scholar 

  24. Trombetta M, Julian T, Bhandari T, Werts ED, Miften M, Parda D. Breast conservation surgery and interstitial brachytherapy in the management of locally recurrent carcinoma of the breast: the Allegheny General Hospital experience. Brachytherapy. 2008;7:29–36.

    Article  PubMed  Google Scholar 

  25. Trombetta M, Julian TB, Werts DE, et al. Long-term cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast. Am J Clin Oncol. 2009;32:314–8.

    Article  PubMed  Google Scholar 

  26. Forman DL, Chiu J, Restifo RJ, Ward BA, Haffty B, Ariyan S. Breast reconstruction in previously irradiated patients using tissue expanders and implants: a potentially unfavorable result. Ann Plast Surg. 1998;40:360–3. discussion 3–4.

    Article  PubMed  CAS  Google Scholar 

  27. Habel LA, Achacoso NS, Haque R, et al. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009;11:85.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117–28.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Punglia RS, Schnitt SJ, Weeks JC. Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate? J Natl Cancer Inst. 2013;105(20):1527–33.

    Article  PubMed  CAS  Google Scholar 

  30. Punglia RS, Burstein HJ, Weeks JC. Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer. 2012;118(3):603–11.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Soeteman DI, Stout NK, Ozanne EM, Greenberg CC, Hassett MJ, Schrag D, et al. Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Can Inst. 2013;105(11):774–781.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by Contract No. HHSA29020050016I from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions About Effectiveness program. The views expressed in this article are those of the authors, and no official endorsement by AHRQ or the US Department of Health and Human Services is intended or should be inferred. This work was also supported by grant no. CA89393 from the National Cancer Institute to the Dana-Farber Cancer Institute, Grant No. R01 CA 81302 to Kaiser Permanente Northern California, and grant no. 2U19CA079689 to Group Health Cooperative (Laurel Habel, Project Leader).

Conflict of interest

Caprice C. Greenberg, Laurel A. Habel, Melissa E. Hughes, Larissa Nekhlyudov, Ninah Achacoso, Luana Acton, Deborah Schrag, Wei Jiang, Stephen Edge, Jane C. Weeks, and Rinaa S. Punglia have no financial disclosures or conflicts of interest to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Caprice C. Greenberg MD MPH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greenberg, C.C., Habel, L.A., Hughes, M.E. et al. Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ. Ann Surg Oncol 21, 3766–3773 (2014). https://doi.org/10.1245/s10434-014-3802-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3802-7

Keywords

Navigation